Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate

Executive Summary

Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

You may also be interested in...



UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back

The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV124980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel